| Features: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oleocanthal is essentially found ONLY in: Fresh, unrefined extra-virgin olive oil (EVOO) It is part of the pungent, throat-stinging phenolic fraction that disappears in refined oils. Oleuropein (OLEU) — a secoiridoid polyphenol from olive leaf and olive fruit/extra-virgin olive oil; major in-vivo related phenolic is hydroxytyrosol (via hydrolysis/metabolism). Sources: olive leaf extract (standardized to oleuropein), EVOO phenolics. Primary mechanisms (conceptual rank): Bioavailability / PK relevance: Human data show absorption/metabolism after oral olive leaf extract; circulating forms are largely metabolites (and hydroxytyrosol-related), with limited free parent compound exposure. :contentReference[oaicite:0]{index=0} In-vitro vs oral exposure: Many direct “anticancer” cytotoxic effects occur at micromolar concentrations that may exceed typical systemic exposure from supplements/foods (high concentration only for direct tumor cytotoxicity in many models). :contentReference[oaicite:1]{index=1} Clinical evidence status: Nutraceutical/food bioactive with human data mainly for cardiometabolic/inflammation endpoints; oncology evidence largely preclinical/adjunct-hypothesis (no oncology approval). Also available as a supplement usually labeled as Olive Leaf Extract. (20-50% concentrations)- commonly used in CSC (Cancer Stem Cell) research. Main CSC mechanisms: -Inhibits Wnt/β-catenin — a core CSC survival pathway -↓ALDH (Reduces ALDH-high CSC subpopulations) -downregulates stemness geens: SOX2/OCT4/Nanog → reduced sphere formation/self-renewal. Oleuropein — Cancer vs Normal Cell Pathway Map
TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr Oleuropein — AD relevance: Oleuropein/olive leaf phenolics show neuroprotection in models via oxidative- and heat-shock/proteostasis stress responses, with reported reduction of Aβ and tau proteotoxicity in preclinical systems; human AD disease-modifying evidence is not established. Primary mechanisms (conceptual rank): Bioavailability / PK relevance: Human absorption/metabolism supports systemic exposure mainly as metabolites; brain relevance likely chronic/adaptive. :contentReference[oaicite:9]{index=9} Clinical evidence status: Predominantly preclinical for AD mechanisms; limited AD-specific clinical endpoint evidence. Oleuropein — AD / Neurodegeneration Pathway Map
TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr |
| Source: |
| Type: |
| Normal cells grow and divide in a regulated manner through the cell cycle, which consists of phases (G1, S, G2, and M). Cancer cells often bypass these regulatory mechanisms, leading to uncontrolled proliferation. This can result from mutations in genes that control the cell cycle, such as oncogenes (which promote cell division) and tumor suppressor genes (which inhibit cell division). |
| 4627- | OLE, | Oleuropein regulates ubiquitination-mediated Mcl-1 turnover and exhibits antitumor activity |
| - | in-vitro, | Oral, | NA |
| 4629- | OLE, | Oleuropein exhibits anticancer effects by inducing apoptosis and inhibiting cell motility in MCF7 and MDA-MB231 breast cancer cells |
| - | in-vitro, | BC, | MDA-MB-231 | - | NA, | NA, | MCF-7 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:375 Target#:323 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid